CA-TRICENTIS
15.1.2020 19:24:05 CET | Business Wire | Press release
Tricentis, the leader in continuous testing for DevOps, announced that it has acquired SpecFlow, the biggest and most trusted BDD solution for .NET developers around the world. SpecFlow’s pragmatic approach to specification-by-example has helped agile development teams improve collaboration with business stakeholders to build and deliver higher quality software.
SpecFlow will continue to remain a free, open source offering for the software development and testing communities. SpecFlow+ , SpecFlow’s commercial offering, and SpecMap , an Azure DevOps extension for user story mapping, will now be offered for free to meet the needs of scaling BDD across the enterprise – all backed by Tricentis’ leading innovation in continuous testing.
With this acquisition, Tricentis continues to extend its leadership in the open source and developer-led testing market. SpecFlow is Tricentis’ second acquisition in this market within the past year, with further acquisitions planned in the coming months. In 2019, Tricentis acquired TestProject , the world’s first free, cloud based test automation platform leveraging Selenium and Appium. The acquisition of SpecFlow adds best-in-class support for BDD and .NET developers to round out Tricentis’ comprehensive open source testing platform.
“BDD is becoming broadly relevant in enterprises for their digital transformation,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “As business requirements change at DevOps speed, teams need a way to document how their applications should behave across highly integrated systems. Without built-in test automation to this shared understanding, software delivery leads to production bugs and poor user experiences. SpecFlow’s ability to create this shared business understanding, connected with automated tests, makes it the most trusted BDD platform for .NET development.”
SpecFlow was developed by TechTalk as the open source port of Cucumber for .NET in 2009. Since then, SpecFlow has gathered a massive open source community, with more than 9.6 million downloads and a user base that continues to grow at more than 3,000 downloads per day.
SpecFlow provides a way to define, manage and automatically execute human-readable acceptance tests in .NET projects. By using human-readable syntax, known as Gherkin (“Given-When-Then”), SpecFlow helps software delivery teams to create a common business understanding of how their systems should behave. Its integration with popular developer tools like Selenium and Microsoft Visual Studio have made SpecFlow the BDD standard to bridge the communication gap between developers, testers and business users.
“I’m extremely proud of the community that SpecFlow has fostered over the years,” said Christian Hassa, Owner and Managing Partner at TechTalk. “TechTalk is happy to have found a partner in Tricentis who is committed to the BDD community and to significantly expand on our vision for SpecFlow while keeping it independent.”
About SpecFlow
SpecFlow is the world’s leading open-source Behavior-Driven Development framework for .NET. SpecFlow facilitates collaboration between teams in small and large enterprises, allows you to automate tests written in human-readable language, and helps stakeholders build up a shared understanding of software systems. Learn more about SpecFlow at https://specflow.org .
About TechTalk
TechTalk is a Central European company that specializes in agile methods, agile development, and agile coaching. TechTalk was a first mover in the agile community, realized the potential of Behavior-Driven Development at an early stage and started developing SpecFlow in 2008. TechTalk released SpecFlow as an open-source project in 2009 to involve the agile community and accelerate the growth and adoption of SpecFlow. Learn more about TechTalk at https://techtalk.at or follow us on LinkedIn , Twitter .
About Tricentis
With the industry’s #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases–transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.
Tricentis is the only vendor to achieve “Leader” status in all three top analyst reports (i.e., the “Triple Crown”). This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1600+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent–increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.
Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn , Twitter , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005741/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom